Revisiting the Plasmodium falciparum druggable genome using predicted structures and data mining.

  • Journal Article
  • Preprint

Journal:
Research square
Published:
November 26, 2024
PMID:
39649165
Authors:
Karla P Godinez-Macias KP, Daisy Chen D, J Lincoln Wallis JL, Miles G Siegel MG, Anna Adam A, Selina Bopp S, Krypton Carolino K, Lauren B Coulson LB, Greg Durst G, Vandana Thathy V, Lisl Esherick L, Madeline A Farringer MA, Erika L Flannery EL, Barbara Forte B, Tiqing Liu T, Luma Godoy Magalhaes LG, Anil K Gupta AK, Eva S Istvan ES, Tiantian Jiang T, Krittikorn Kumpornsin K, Karen Lobb K, Kyle McLean K, Igor M R Moura IMR, John Okombo J, N Connor Payne NC, Andrew Plater A, Srinivasa P S Rao SPS, Jair L Siqueira-Neto JL, Bente A Somsen BA, Robert L Summers RL, Rumin Zhang R, Michael K Gilson MK, Francisco-Javier Gamo FJ, Brice Campo B, Beatriz BaragaƱa B, James Duffy J, Ian H Gilbert IH, Amanda K Lukens AK, Koen J Dechering KJ, Jacquin C Niles JC, Case W McNamara CW, Xiu Cheng X, Lyn-Marie Birkholtz LM, Alfred W Bronkhorst AW, David A Fidock DA, Dyann F Wirth DF, Daniel E Goldberg DE, Marcus C S Lee MCS, Elizabeth A Winzeler EA
Abstract:

The identification of novel drug targets for the purpose of designing small molecule inhibitors is key component to modern drug discovery. In malaria parasites, discoveries of antimalarial targets have primarily occurred retroactively by investigating the mode of action of compounds found through phenotypic screens. Although this method has yielded many promising candidates, it is time- and resource-consuming and misses targets not captured by existing antimalarial compound libraries and phenotypic assay conditions. Leveraging recent advances in protein structure prediction and data mining, we systematically assessed the genome for proteins amenable to target-based drug discovery, identifying 867 candidate targets with evidence of small molecule binding and blood stage essentiality. Of these, 540 proteins showed strong essentiality evidence and lack inhibitors that have progressed to clinical trials. Expert review and rubric-based scoring of this subset based on additional criteria such as selectivity, structural information, and assay developability yielded 67 high priority candidates. This study also provides a genome-wide data resource and implements a generalizable framework for systematically evaluating and prioritizing novel pathogenic disease targets.


Courtesy of the U.S. National Library of Medicine